Loading news...
Axim Planning and Wealth purchased a new position in Colgate-Palmolive Company (NYSE: CL) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 6,959 shares of the company's stock, valued at approximately $556,000. Several other institutional investors and hedge funds have also
Insight into Diamond Hill Capital (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Diamond Hill Capital (Trades, Portfolio) recently submitted its 13F fili
NEW YORK--(BUSINESS WIRE)--Colgate-Palmolive (NYSE:CL) Chairman, President and CEO, Noel Wallace, and SVP, Global Growth and Innovation, Hill's Pet Nutrition, Caroline Chulick, will present on Friday, February 20, 2026 at 8:00 am ET at the Consumer Analyst Group of New York Conference. Investors may access a live webcast of this presentation and the presentation slides on Colgate's website at www.colgatepalmolive.com. For those unable to participate during the live webcast, a recorded version o.
Callan Family Office LLC trimmed its stake in shares of Colgate-Palmolive Company (NYSE: CL) by 37.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,702 shares of the company's stock after selling 6,983 shares during the quarter. Callan Family
Colgate-Palmolive's high returns in recent months are a direct result of the extremely negative investor sentiment in 2025. Although the stock now trades much closer to its fair value, margin improvements in 2026 will continue to support the stock price. The stock's 5-year beta of 0.3 underscores its low-risk profile, making it very attractive during the current period of heightened risk of equities.
Colgate-Palmolive remains a Buy as it enters its next 5-year plan, leveraging strong brands and resilient financials. Q4 earnings beat expectations, with record cash flow from operations and robust performance in emerging markets driving a 5.9% revenue increase. Guidance reflects uncertainty, projecting 2–6% net sales growth and 1–4% organic sales growth, while CL advances its $5B buyback and maintains a solid payout.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Colgate-Palmolive, a Dividend King with 63 years of dividend increases to its name, is trading up 16.8% so far in 2026. Yet for a much longer period, the stock's total return badly trailed that of the S&P 500.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Colgate-Palmolive Company (NYSE: CL) posted better-than-expected fourth-quarter earnings on Friday.
Colgate-Palmolive (NYSE: CL) executives said the company delivered "stronger-than-expected" fourth-quarter results and ended 2025 with improving momentum, while emphasizing that 2026 will begin under a highly uncertain operating backdrop as the company launches its new 2030 strategy. On the company's fourth-quarter and full-year 2025 earnings call, Chairman, President and CEO Noel Wallace said Colgate delivered growth
Dividend Aristocrats underperformed the S&P 500 in 2025, with NOBL returning 6.82% versus SPY's 17.70%. 2026 began strong for Aristocrats, with NOBL gaining 5.67% in January, outpacing SPY's 1.47%. Dividend growth for Aristocrats averaged 5.52% in 2025, but early 2026 increases trend slightly lower, raising questions for the year's outlook.
Organic Sales Growth: Achieved growth in all four categories in Q4, with sequential improvement in every division except North America.Net Sales: Added $5 bill
Colgate-Palmolive Company (CL) Q4 2025 Earnings Call Transcript
CL's Q4 earnings beat estimates as strong pricing and brand leadership lifted sales, with solid gains in Latin America and resilient global demand.
In a week of stock market newsworthiness, the hits keep coming this Friday morning. President Trump's new Fed Chair has been announced: former Fed Governor Kevin Warsh.
Although the revenue and EPS for Colgate-Palmolive (CL) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Colgate-Palmolive stock was up on the back of strong quarterly earnings.
Colgate-Palmolive (CL) came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.91 per share a year ago.
Colgate-Palmolive swung to a loss in the fourth quarter, hurt by a large charge tied to its struggling skin-health business, but sales climbed despite what the company says is a difficult environment.